¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement control protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® protein ÇÑ±Û ´Ü¹éÁú
¼³¸í   
  Åº¼Ò, ¼ö¼Ò, »ê¼Ò, Áú¼Ò, È²À» ÇÔÀ¯Çϰí Àִ À¯±âÈ­ÇÕ¹°·Î, ¸ðµç ¼¼Æ÷ÀÇ ¿øÇüÁúÀ» ÀÌ·ç°í Àִ ±âº» ±¸¼º¹°ÁúÀÌ´Ù. ´Ü¹éÁúÀº ±× ´ÜÀ§ÀΠ¾Æ¹Ì³ë»êµéÀÌ ÆéƼµå°áÇÕ¿¡ ÀÇÇØ °áÇյǾî ÀÖÀ¸¸ç, º¸Åë 20°³ÀÇ ¾Æ¹Ì³ë»êµéÀÌ ´Ù¸¥ ¼ø¼­¿Í Á¶¼ºÀ» °¡Áö°í ¹è¿­µÇ¾î, µ¶Æ¯ÇÑ ÇϳªÀÇ ´Ü¹éÁúÀ» Çü¼ºÇϰԠµÈ´Ù.
¿µ¹® quality control ÇÑ±Û Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
¼³¸í   
  °úÇÐÀû ¿ø¸®¸¦ ÀÀ¿ëÇÏ¿© Á¦Ç°Ç°ÁúÀÇ À¯Áö-Çâ»óÀ» ±âÇϱâ À§ÇÑ °ü¸®. ³ÐÀº ¶æÀ¸·Î´Â °¡Àå ½ÃÀ强ÀÌ ³ôÀº Á¦Ç°À» °¡Àå °æÁ¦ÀûÀ¸·Î »ý»êÇϱâ À§ÇÑ ÀÏ·ÃÀǠü°ÔÀû Á¶Ä¡¸¦ °¡¸®Å°³ª, ÀϹÝÀûÀ¸·Î´Â ¾ÕÀÇ Á¼Àº ¶æÀÇ ÇØ¼®ÀÌ Åë¿ëµÈ´Ù. ÃʱâÀÇ QC´Â ÀüÁ¦Ç°¿¡ ´ëÇØ Ä¡¼ö-Áß·®-üÀûÀ̳ª Àç·áÀÇ È­ÇÐÀû ¼ººÐ µîÀ» ÃøÁ¤Çϰí, ±×°ÍÀ» ¹Ì¸® Á¤ÇØ ³õÀº Ç°ÁúÇ¥Áذú ºñ±³ÇÏ¿© ÀûºÎ¸¦ ÆÇÁ¤Çϴ ¹æ¹ýÀÌ ÃëÇØÁ³´Ù.
¿µ¹® complement ÇÑ±Û º¸Ã¼
¼³¸í   
  Ç×ü¿Í ¹ÝÀÀÇÏ¿© Ç×ü¿Í °áÇյȠ¼¼Æ÷ÀÇ ÆÄ±«¸¦ ÀÏÀ¸Å°´Â ´Ü¹éÁúÀ» ¸»ÇÑ´Ù. Ç×ü°¡ Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ Àִµ¥ ±× ÁßÀÇ Çϳª·Î Ç×ü¿Í °áÇÕÇÑ ¼¼Æ÷ÀǠǥ¸éÀ» ºÎºÐÀûÀ¸·Î ¼Õ»ó½ÃÄÑ ±× ¼¼Æ÷¸¦ ÆÄ±«Çϴ ¿ªÇÒÀ» Çϴ °ÍÀÌ ÀÌ º¸Ã¼ÀÌ´Ù. º¸Ã¼´Â 20°¡ÁöÀÇ ´Ü¹éÁú·Î ±¸¼ºµÇ¾î Àִµ¥ ¾àÀڷΠC·Î Ç¥½ÃÇϸ砰¢ Á¾·ù¸¦ ³ªÅ¸³¾ °æ¿ì¿¡´Â C¿·¿¡ ¼ýÀÚ¸¦ ½á¼­ Ç¥½ÃÇÑ´Ù.
¿µ¹® complement fixation reaction ÇÑ±Û º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¼³¸í   
  Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ À־ º¸Ã¼¿Í °áÇÕÇϴ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼­´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇϴ ¿ëÇ÷¼ÒÀǠȥÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀϾ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼­ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉí, Å¬¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • membrane control protein
    ¸·Á¶Àý´Ü¹éÁú
  • alternative complement pathway
    ´ëüº¸Ã¼°æ·Î
  • classic complement pathway
    ÀüÇüÀûº¸Ã¼°æ·Î
  • complement
    º¸Ã¼, µµ¿òü
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • complement cascade
    º¸Ã¼¿¬¼â¹ÝÀÀ, µµ¿òü¿¬¼â¹ÝÀÀ
  • complement component
    º¸Ã¼¼ººÐ, µµ¿òü¼ººÐ
  • complement fixation
    º¸Ã¼°áÇÕ
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ
  • complement fixation test
    º¸Ã¼°áÇÕ°Ë»ç
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement profile
    º¸Ã¼Ãø¸é»ó
  • complement receptor
    º¸Ã¼¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    µµ¿òü, º¸Ã¼
  • complement cascade
    µµ¿òü¿¬¼â¹ÝÀÀ, º¸Ã¼¿¬¼â¹ÝÀÀ
  • complement fixation reaction
    µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
  • protein binding
    ´Ü¹é°áÇÕ
  • control
    1. ÅëÁ¦, Á¦¾î, 2. ´ëÁ¶, 3. °ü¸®
  • quality control
    Á¤µµ°ü¸®, ǰÁú°ü¸®, Áú°ü¸®
  • reflex control
    ¹Ý»çÁ¶Àý
  • safety control
    ¾ÈÀü°ü¸®
  • sugar control
    Ç÷´çÁ¶Àý
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • protein-losing enteropathy
    ´Ü¹é¼Ò½ÇâÀÚº´Áõ
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • adherence protein
    ºÎÂø´Ü¹é
  • reserve protein
    ÀúÀå´Ü¹é
  • split-timed urine protein
    ½Ã°£´ëº°¿ä´Ü¹éÁ¤·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • membrane control protein
    ¸·Á¶Àý´Ü¹é
  • alternative complement pathway
    º¸Ã¼´ëü°æ·Î, µµ¿òü´ëü°æ·Î
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • complement-fixing antibody
    µµ¿òü°áÇÕÇ×ü, º¸Ã¼°áÇÕÇ×ü
  • complement
    µµ¿òü, º¸Ã¼
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • complement-mediated
    µµ¿òü¸Å°³-
  • classic complement pathway
    º¸Ã¼ÀüÇüÀû°æ·Î, µµ¿òüÀüÇüÀû°æ·Î
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    µµ¿òü¼ººÐ
  • complement deficiency
    µµ¿òü°áÇÌ
  • complement fixation
    µµ¿òü°áÇÕ
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • complement profile
    µµ¿òÃ¼Ãø¸é»ó
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • gonococcal complement fixation test
    ÀÓ±Õº¸Ã¼°áÇÕ¹ÝÀÀ°Ë»ç.
  • heparin complement
    ÇìÆÄ¸°º¸Ã¼.
  • inactivation of complement
    º¸Ã¼ºñµ¿È­.
  • indirect complement fixation test
    °£Á¢º¸Ã¼°áÇÕ½ÃÇè
  • AGC (automatic gain control)
    ÀÚµ¿ °ÔÀÎ Á¶Àý
  • AGC (automatic gain control)
    ÀÚµ¿ (í»ÔÑ) °ÔÀÎ Á¶Àý (ðàï½), À̵æÀÚµ¿Á¶Àý
  • Control system
    Á¶Àý°è(ðàï½Í§)
  • Levey Jennings control chart
    ·¹ºñÁ¦´×½º°ü¸®µµ
  • Westgard quality control test
    ¿þ½ºÆ®°¡µåÁ¤µµ°ü¸®°Ë»ç¹ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement-induced = complement-mediated
    º¸Ã¼¸Å°³¼º
  • membrane control protein
    ¸·Á¶Àý´Ü¹é
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • autoimmune complement fixation =AICF
    ÀÚ±â¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(¡­ÜÍô÷Ì¿ùêÚãëë).
  • autoimmune complement fixation =AICF
    ÀÚ°¡¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(¡­ÜÍô÷Ì¿ùêÚãëë).
  • autoimmune complement fixation =AICF
    ÀÚ±â¸é¿ª¼º º¸Ã¼°áÇÕ¹ÝÀÀ(?ËÓ̧˭̰ËÑËô).
  • complement
    º¸Ã¼(ÜÍô÷), º¸Ãæ(ÜÍõö).
  • complement
    º¸Ã¼(ÜÍô÷)
  • complement
    º¸Ã¼
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë(¡­üÀàõíÂéÄ), º¸Ã¼È°¼ºÈ­.
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë
  • complement binding antibody
    º¸Ã¼°áÇÕÇ×ü(ÜÍô÷Ì¿ùêù÷ô÷).
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    º¸Ã¼¼ººÐ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Protein granule
    ´Ü¹éÁú°ú¸³
    [¿¾ ¿ë¾î] ´Ü¹éÁú°ú¸³
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insect control
    °ïÃæ±¸Á¦, °ïÃæ¹æÁ¦
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • circumsporozoite protein (CSP)
    Æ÷ÀÚ¼Òü¸·´Ü¹éÁú
  • protein layer
    ´Ü¹éÁúÃþ
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • autoimmune complement fixation
    ÀÚ°¡¸é¿ª (í»Ê«Øóæ¹) º¸Ã¼°íÁ¤ (ÜÍô÷ͳïÒ)
  • complement
    º¸Ã¼(ÜÍô÷)
  • complement activation
    º¸Ã¼ Ȱ¼ºÈ­(ÜÍô÷üÀàõûù)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • complement fixation
    º¸Ã¼°íÁ¤(ÜÍô÷ͳïÒ)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • complement fixation test
    º¸Ã¼°íÁ¤½ÃÇè(ÜÍô÷ͳïÒãËúÐ)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • indirect complement fixation test
    °£Á¢º¸Ã¼°íÁ¤½ÃÇè(ÊàïÈÜÍô÷ͳïÒãËúÐ)
  • acceptor control
    ¼ö¿ëü Á¦¾î (â¥é»ô÷ ð¤åÙ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • adenylate control hypothesis
    ¾Æµ¥´Ò»ê(ß«)Á¶Àý¼³(ðàï½àã)
  • autogenous control
    ÀÚÀÎÁ¶Àý (í»ì×ðàï½)
  • control
    "´ëÁ¶(ÓßðÎ), Á¶Àý(ðàï½), Á¦¾î(ð¤åÙ)"
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    º¸Ã¼, º¸Ãæ
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
  • AGC [=automatic gain control]
    ÀÚµ¿°ÔÀÎÁ¶Àý
  • control
    ´ëÁ¶, Á¶Àý, Á¦¾î, °ü¸®, ±ÔÁ¦, ¹æÁ¦
  • control group
    ´ëÁ¶±º
  • equipment quality control
    ÀåÄ¡ÀÇ ¼º´É°ü¸®
  • pulse control unit
    ¸Æ¹ÚÁ¶Àý´ÜÀ§
  • quality control
    È­Áú°ü¸®, ǰÁú°ü¸®
  • remote control
    ¿ø°ÝÁ¶Á¾, ¿ø°ÝÁ¶ÀÛ
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
  • Bence-Jones protein
    º¥½º-Á¸½º´Ü¹é
  • C-reactive protein
    C-¹ÝÀÀ¼º´Ü¹éÁú
  • high protein diet
    °í´Ü¹é½ÄÀÌ
  • plasma protein
    Ç÷Àå´Ü¹éÁú
  • protein
    ´Ü¹é(Áú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CCP Complement Control Protein
VCP virus complement control protein
Control control
control group control
CRP complement regulatory protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • complement activation
    º¸Ã¼ Ȱ¼º ÀÛ¿ë, º¸Ã¼ Ȱ¼ºÈ­
  • complement consumption test
    º¸Ã¼ ¼Òºñ ½ÃÇè
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • complement fixation test
    º¸Ã¼ °áÇÕ ½ÃÇè, º¸Ã¼ °áÇÕ °Ë»ç, º¸Ã¼ °íÁ¤ °Ë»ç
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
  • complement splitting
    º¸Ã¼ ºÐÇØ
  • complement-mediated cytotoxicity
    º¸Ã¼ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • inactivation of complement
    º¸Ã¼ ºñµ¿È­
  • serum complement titer
    Ç÷û º¸Ã¼ °¡ÃøÁ¤
    ¸ðµç º¸Ã¼ Ȱ¼ºÀÇ ÃÑÇÕÀ¸·Î¼­ ÃøÁ¤µÈ´Ù.
  • treponema pallidum complement fixation test
    Æ®·¹Æ÷³×¸¶ º¸Ã¼ °áÇÕ ½ÃÇè
  • admission by legal control
    Á¶Ä¡ ÀÔ¿ø
  • birth control
    ÇÇÀÓ¹ý
    ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ´Â ÀÏ. Àü¿¡´Â »ê¾Æ Á¦ÇÑ, Ãâ»ê Á¶ÀýÀ̶ó°í ÇßÀ¸³ª Á¶Àý ´ë»óÀº ºÐ¸¸ÀÌ ¾Æ´Ï°í ¼öÅÂÀ̱⠶§¹®¿¡ ¼öÅ Á¶Àý·Î °³Á¤µÇ¾ú´Ù. ¸ðüÀÇ °Ç°­À̳ª °æÁ¦ÀûÀÎ ÀÌÀ¯ µîÀ¸·Î ÀÓ½ÅÇØ¼­´Â °ï¶õÇÑ »çÁ¤ÀÌ ÀÖÀ» ¶§ ÇÇÀÓÀ» °è¼ÓÇϰí, ¾ÆÀ̰¡ ÇÊ¿äÇØÁö¸é ÇÇÀÓÀ» ÁßÁöÇϰí ÀÓ½ÅÇÒ ¼ö ÀÖµµ·Ï ÀÎÀ§ÀûÀÎ ¼ö´ÜÀ» »ç¿ëÇØ¼­ ¼öŸ¦ ÀΰøÀûÀ¸·Î Á¶ÀýÇÏ¿© »ê¾Æ¸¦ Á¦ÇÑÇÏ´Â °ÍÀÌ´Ù. ÀÌ¹Ì ÀÓ½ÅÇÑ °ÍÀ» ÀΰøÀûÀ¸·Î ÁßÀýÇÏ´Â °ÍÀº ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾Ê´Â´Ù. Áï, ÇÇÀÓÀÇ ½ÇÆÐ´Â µµ¸®°¡ ¾ø±â ¶§¹®¿¡ ¹Ù¸¥ ÇÇÀÓÀÇ Áö½ÄÀ» ¾ò¾î ÀûÀýÇÑ ÇÇÀÓ¹ýÀ» ¼±ÅÃÇØ¼­ ¹Ù¸£°Ô ½ÃÇàÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. ¼öÅ Á¶Àý¿¡ ÀÀ¿ëµÇ´Â ÇÇÀÓ¹ýÀº ¼öÁ¤ ÀúÁö¹ý°ú ¼öÅ ÀúÁö¹ýÀ¸·Î ´ëº°µÇÁö¸¸ ¸ðµÎ ÀϽÃÀûÀÎ ÇÇÀÓ¹ýÀÌ´Ù. À̰ÍÀº ±¹°¡°¡ ÁÖüÀÎ °æ¿ì¿¡´Â Àα¸ Á¤Ã¥ÀÌ µÇ¸ç, °¡Á¤ÀÌ ÁÖüÀÎ °æ¿ì¿¡´Â °¡Á· °èȹÀÌ µÇ´Â °¡Àå ÇÕ¸®ÀûÀÎ ¼ö´ÜÀÌ´Ù. ½Ç¿ëÀûÀÎ ¸é¿¡¼­ ºÐ·ùÇÑ ÇÇÀÓ¹ýÀº ´ÙÀ½°ú °°´Ù. ¡¼¹è¶õÀÏ ÀüÈÄÀÇ ¼º±³¸¦ ÇÇÇÏ´Â ¹æ¹ý¡½ ¹è¶õÀÏ ÀüÈÄ ¼öÀϰ£À» ±Ý¿åÇÔÀ¸·Î½á ¼öÁ¤À» ¹Ì¸® ¸·´Â °ÍÀ¸·Î, ¹è¶õÀÏÀ» ¿¹»óÇÏ´Â ¹æ¹ý¿¡´Â 2°¡Áö°¡ ÀÖ´Ù. ¨ç ¿À±â³ë½Ä ¼öÅ Á¶Àý¹ý : Çѱ¹¿¡¼­ °¡Àå ³Î¸® º¸±ÞµÇ¾î ÀÖ´Â ¹æ¹ýÀ¸·Î, ¿ù°æ ÁֱⰡ Á¤È®ÇÏ°Ô µ¹¾Æ¿À´Â ¿©¼º¿¡°Ô¸¸ Àû¿ëÀÌ °¡´ÉÇÏ´Ù. 28ÀÏÇüÀÎ ¿©¼ºÀÇ °æ¿ì ¿ù°æ Á¦1ÀϰºÎÅÍ ¼¼¾î¼­ Á¦14Àϰ°¡ µÇ´Â ³¯ÀÇ Àü 3Àϰ£°ú ÈÄ 2Àϰ£ÀÌ °¡Àå ÀÓ½ÅÇϱ⠽¬¿î ³¯·Î º¸°í ÀÌ ±â°£Àº ¼º±³¸¦ ÇÇÇÑ´Ù. ÀÌ ¹æ¹ýÀº ¿ù°æ ÁֱⰡ ºÒ±ÔÄ¢ÇÑ ¿©¼ºÀÇ °æ¿ì¿¡´Â ½ÇÆÐÀÇ È®·üÀÌ Å©´Ù. ¨è ±âÃÊ Ã¼¿ÂÇ¥¸¦ ÀÀ¿ëÇÏ´Â ¹æ¹ý : ¸ÅÀÏ ±âÃÊ Ã¼¿ÂÀ» ÃøÁ¤Çؼ­ ±âÃÊ Ã¼¿Â °î¼±ÀÌ °í¿Â»óÀÌ µÇ¾î 2ÀÏÀÌ °æ°úÇßÀ» ¶§´Â °ÅÀÇ ÀÓ½ÅÇÏÁö ¾Ê´Â °ÍÀ¸·Î ³ªÅ¸³ª ÀÖ¾î 3ÀÏ ÀÌÈĺÎÅÍ ¼º±³¸¦ °®´Â ¹æ¹ýÀÌÁö¸¸, °í¿Â»óÀÎÁö Àú¿Â»óÀÎÁö¸¦ Á¤ÇϱⰡ ¶§·Î´Â °ï¶õÇÑ ¶§°¡ ÀÖ´Ù. ¡¼³²¼ºÀÌ ÇÇÀÓ µµ±¸³ª ¾àǰÀ» »ç¿ëÇÏ´Â ¹æ¹ý¡½ ³²¼ºÀÌ ¼º±³ ¶§ Äܵ¼À» ½á¼­ ¼öÁ¤À» ÀúÁöÇÏ´Â ¹æ¹ýÀÌ °¡Àå ÀϹÝÀûÀÌ´Ù. Äܵ¼Àº ³²¼º ¼º±â¿¡ ¾º¿ö¼­ »ç¿ëÇÏ´Â ¾ãÀº °í¹« Á¦Ç°ÀÎ Á¡¿¡¼­ ³²¼ºÀÌ »ç¿ë°¨À» °¡Áö°Ô ÇÑ´Ù´Â °áÁ¡ÀÌ ÀÖ°í, ¿©¼º¿¡°Ô´Â ½É¸®ÀûÀÎ ¹®Á¦¸¦ Æ÷ÇÔÇÏ¿© ¿©·¯ °¡Áö °áÁ¡ÀÌ ÁöÀûµÇ°í ÀÖÁö¸¸, ½ÇÆÐÀ²ÀÌ ³·°í ÀϹÝÀûÀ¸·Î ½±°Ô ±¸ÇÒ ¼ö ÀÖÀ¸¸ç ´©±¸³ª »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ´Ù¸¥ ¹æ¹ý¿¡ ºñÇØ ÀåÁ¡ÀÌ´Ù. ƯÈ÷ ÃÖ±Ù¿¡´Â °í¹«ÀÇ ÁúÀÌ °³·®µÇ°í Á¦Ç°ÀÇ Ç°ÁúÀÌ Çâ»óµÇ¾î ÆÄ¼ÕÀÇ ¿ì·Áµµ ¾ø´Ù. ÀÌ ¹Û¿¡ Á¤ÀÚ¸¦ ¸¸µå´Â ÈûÀ» ¾àÈ­½Ãų ¸ñÀûÀ¸·Î ³²¼º¿¡°Ô ÇÇÀÓ ¾àÀ» ¾²°Ô ÇÏ´Â °æ¿ìµµ ÀÖÀ¸³ª, ÇÇÀÓÀÇ ¸ñÀûÀº ´Þ¼ºÇß´Ù ÇØµµ °¡²û ³²¼ºÀÇ ¼º¿åÀ» ÀúÇϽÃŲ´Ù ÇÏ¿© ½Ç¿ëµÇÁö ¾Ê°í ÀÖ´Ù. ¡¼ÁßÀý ¼º±³¹ý¡½»çÁ¤ Àü¿¡ ¼º±³¸¦ Áß´ÜÇϰí Áú ¿ÜºÎ¿¡ »çÁ¤ÇÏ´Â ¹æ¹ýÀε¥ Áú ¾È¿¡ Á¤¾×À» µé¿©º¸³»Áö ¾Êµµ·Ï ÇØ¼­ ÀÓ½ÅÀ» ÇÇÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. ÀÌ ¹æ¹ýÀº Ưº°ÇÑ ±â±¸¸¦ ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç ¾î·Á¿ò ¾øÀÌ ÇÒ ¼ö ÀÖ´Â ÀåÁ¡µµ ÀÖÁö¸¸, ÇÇÀÓÀ̶ó´Â ¸ñÀû ¶§¹®¿¡ ¼º°¨À» Èñ»ýÇÏ°Ô µÇ´Â °æÇâÀÌ °­ÇÏ´Ù. ´õ¿íÀÌ °áÁ¤ÀûÀÎ °áÁ¡Àº ÀÓ½ÅÀÇ À§Çèµµ Å©´Ù´Â Á¡ÀÌ´Ù. ¡¼¿©¼ºÀÌ ±â±¸¸¦ »ç¿ëÇÏ´Â ¹æ¹ý¡½¨ç Æä¼­¸®
  • bite control
    ±³ÇÕ Á¶Á¤
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ Á¶Á¤ÇÏ´Â °Í.
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • control animal
    ´ëÁ¶ µ¿¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
male chromosome complement The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes).
(12 Dec 1998)
genetic complement <biology, genetics> The set of chromosomes contained within any one particular cell.
(07 May 1998)
receptors, complement Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement.
(12 Dec 1998)
receptors, complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
(12 Dec 1998)
receptors, complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor.
(12 Dec 1998)
chromosome complement The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes.
(12 Dec 1998)
complement <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions.
Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9.
C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a.
The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules.
The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex.
Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors.
(05 Jan 1998)
complement 1 The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence.
(12 Dec 1998)
complement 1 inactivators Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily.
(12 Dec 1998)
complement 1q <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors.
Chemical name: Complement C1q
(12 Dec 1998)
complement 1r <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage.
Registry number: EC 3.4.21.41
(12 Dec 1998)
complement 1s <enzyme> The activated form of complement 1 which has hydrolase activity. In the classical pathway, it splits first c4 and then c2 into active components, thereby generating a new enzyme referred to as eac142 or c42 or c3 convertase.
Registry number: EC 3.4.21.42
(12 Dec 1998)
complement 2 The third component in the complement reaction sequence. It is a beta-globulin with a molecular weight of 117,000, a serum concentration of 30 micrograms/ml and a sedimentation coefficient of 4. It activates c3.
(12 Dec 1998)
complement 3 The fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5, a molecular weight of 185,000 and a serum concentration of 1.3 micrograms/ml. Its fragments have anaphylatoxic, chemotactic, and histaminic action and affect smooth muscle.
(12 Dec 1998)
complement 3a <chemical> Smaller fragment formed when c3 convertase splits c3 into c3a and c3b. C3a is a 77-amino acid peptide that includes a carboxy-terminal arginine which is crucial for its biological activities. C3a causes symptoms of immediate hypersensitivity (anaphylaxis) including smooth muscle contraction, mast cell histamine release, and local inflammation. It is considered an anaphylatoxin along with c4a, c5a, and c5a des-arginine.
Chemical name: Complement C3a
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
complement control protein (CCP) any of a superfamily of proteins involved in complement regulation, encoded in a closely linked gene cluster, and having one or more stretches of a common short consensus repeat encoding a 60 amino acid domain. Included are factor H, C4 binding protein, decay accelerating factor, membrane cofactor protein, and several complement receptors. Called also regulator of complement activation.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í
  • complement
    º¸ÃæÇÏ¿© ¿ÏÀüÇÏ°Ô ÇÏ´Â °Í;º¸¿Ï¹°;¿©¼ö;¿©°¢;¿©È£;º¸ÃæÀ½Á¤;(ÇÊ¿äÇÑ)Àü¼ö;Àü·®;½Â¹«¿ø Á¤¿ø;º¸ÃæÇÏ¿© ¿ÏÀüÄÉÇÏ´Ù;º¸¿Ï(º¸Ãæ)ÇÏ´Ù;...ÀÇ º¸¿ÏÀÌ µÇ´Ù
  • complement fixation
    º¸Ã¼ °áÇÕ
  • protein
    ´Ü¹éÁú
  • coat protein
    ÇǸ· ´Ü¹é
  • conjugated protein
    º¹ÇÕ ´Ü¹éÁú
  • fish protein concentrate
    ¾îÀ° ³óÃà ´Ü¹é
  • protein
    ´Ü¹éÁú;´Ü¹éÁúÀÇ(À» ÇÔÀ¯ÇÏ´Â). proteinic a.
  • protein clock
    ´Ü¹éÁú ½Ã°è(´Ü¹éÁú ÁøÈ­ ¼Óµµ¸¦ Á¶ÀýÇÏ´Â °¡¼³Àû ü³» ±â±¸)
  • repressor protein
    ¾ïÁ¦ ´Ü¹é(Á¦¾î À¯ÀüÀÚ¿¡ ÀÇÇÏ¿© ¸¸µé¾îÁö´Â ´Ü¹é)
  • bring under control
    Á¦¾î(¾ïÁ¦)ÇÏ´Ù; (ºÒÀ»)²ô´Ù
  • control
    ¾ïÁ¦ÇÏ´Ù,°ü¸®ÇÏ´Ù,Áö¹è,¾ïÁ¦
  • self-control
    ÀÚÁ¦
  • atomic control
    ¿øÀÚ·Â °ü¸® 
  • atonic control
    ¿øÀڷ°ü¸® 6
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á